Study does not demonstrate long-term advantages of regional anaesthesia for breast cancer surgery and dispels misgivings about the influence of opioids on cancer recurrence.
One of the largest global studies in the field of anaesthesia, in which the MedUni Vienna has participated, showed that, following curative breast cancer surgery under regional anaesthesia, the risk of recurrence was not reduced in comparison to general anaesthesia with opioids. These data disprove the assumption that anaesthesia might have a negative impact on breast cancer recurrence. The results have been recently published in “The Lancet”.
The international study was conducted over 10 years and included more than 2,000 women undergoing curative breast cancer surgery. Researchers investigated whether the method of anaesthesia affects the risk of recurrence. For the purposes of the study, patients were followed-up regarding their recurrence rates at regular intervals over a period of several years. Regional anaesthesia did not show advantages in terms of recurrence of breast cancer.
The method of anaesthesia has no influence on the risk of cancer recurrence
Together with colleagues from Cleveland, Dublin, Düsseldorf and Peking, the MedUni Vienna team led by Edith Fleischmann and Peter Marhofer from the Department of Anaesthesia, Critical Care and Pain Medicine of MedUni Vienna and Vienna General Hospital was able to dispel the concerns regarding long-term negative effects of opioids in cancer surgery.
“This should help to counteract the recent concerns against using opioids in anaesthesia,” says Edith Fleischmann, highlighting the significance of the results. In fact, animal trials have shown a correlation between opioids and weakening of the immune system with subsequent effects on tumour growth. “The recent clinical study has shown that opioids do not have any negative impacts on the underlying disease and are an important medical treatment. This is a significant finding for clinical research. We were able to disprove the theory that anaesthesia has a negative impact on tumour growth in breast cancer. At the same time, it demonstrates the importance of clinical trials to validate or – as in this case – refute the results of in vitro and animal studies.
Advantages of regional anaesthesia
The large number of patients included in this study has not only provided robust data, but also add important scientific findings. “Both general anaesthesia and regional anaesthesia are safe anaesthesia methods with very few side-effects and complications,” explains Peter Marhofer. The present study investigated paravertebral blockade for breast cancer surgery, where patients were spontaneously breathing and only sedated. “Paravertebral block has some advantages over general anaesthesia for breast cancer operations,” explains Marhofer, a pioneer of regional anaesthesia, “for example, patients experienced comparatively less pain immediately after the operation and were less likely to suffer from post-operative nausea and vomiting.”
This randomised trial was started under the direction of Daniel Sessler from Cleveland Clinic, USA, and the MedUni Vienna/Vienna General Hospital team included approx 200 patients in the study. This trial investigated only breast cancer recurrence. Future trials are needed in larger operations such as prostate or colo – rectal cancer. They provoke more surgical stress and require more opiods in the perioperative period.
Source: Medical University of Vienna
Reference: The Lancet, Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial; Daniel I Sessler, Lijian Pei, Yuguang Huang, Edith Fleischmann, Peter Marhofer, Andrea Kurz, Douglas B Mayers, Tanja A Meyer-Treschan, Martin Grady, Ern Yu Tan, Sabry Ayad, Edward J Mascha, Donal J Buggy, on behalf of the Breast Cancer Recurrence Collaboration
Published Online October 20, 2019 doi.org/10.1016/S0140-6736(19)32313-X